PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33969575-0 2021 Amplification of DDR2 mediates Sorafenib resistance through NF-kappaB/c-Rel signaling in hepatocellular carcinoma. Sorafenib 31-40 discoidin domain receptor tyrosine kinase 2 Homo sapiens 17-21 33969575-5 2021 The effects of DDR2 on Sorafenib resistance were examined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), colony formation, TdT-mediated dUTP nick end labeling (TUNEL), and flow cytometry assays. Sorafenib 23-32 discoidin domain receptor tyrosine kinase 2 Homo sapiens 15-19 33969575-7 2021 We demonstrated that DDR2 expression was dramatically upregulated in Sorafenib-resistant HCC tissues relative to sensitive tissues. Sorafenib 69-78 discoidin domain receptor tyrosine kinase 2 Homo sapiens 21-25 33969575-8 2021 Downregulation of DDR2 sensitized HCC cell lines to Sorafenib cytotoxicity. Sorafenib 52-61 discoidin domain receptor tyrosine kinase 2 Homo sapiens 18-22 33969575-12 2021 Our results demonstrated that DDR2 is a potential therapeutic target in patients with HCC, and targeting DDR2 represents a promising approach to increase Sorafenib sensitivity in patients with HCC. Sorafenib 154-163 discoidin domain receptor tyrosine kinase 2 Homo sapiens 105-109